Glenmark Life Sciences: March ’22 Results Update
Moneylife Digital Team 22 April 2022
Glenmark Life Sciences (GLS) reported an average set on numbers in Q4FY21-22. GLS is the recently listed API (active pharmaceutical ingredient) arm of Glenmark Pharmaceuticals. We had earlier covered GLS in detail here. In Q4FY21-22, revenue grew by 10% y-o-y (year-on-year), while it declined by 2% q-o-q (quarter-on-quarter) to Rs514 crore. Generic API segment revenue increased by 13% y-o-y,...
Archived Premium Content
This article is outside your subscription period. You can buy this article individually.
SINGLE ARTICLE
Rs 50-Rs 100 + GST
Access will be given ONLY to this article.
 
Already a subscriber ? Log in
Free Helpline
Legal Credit
Feedback